CN109311852A - 作为egfr抑制剂的苯胺嘧啶化合物的结晶 - Google Patents

作为egfr抑制剂的苯胺嘧啶化合物的结晶 Download PDF

Info

Publication number
CN109311852A
CN109311852A CN201780037239.8A CN201780037239A CN109311852A CN 109311852 A CN109311852 A CN 109311852A CN 201780037239 A CN201780037239 A CN 201780037239A CN 109311852 A CN109311852 A CN 109311852A
Authority
CN
China
Prior art keywords
crystal
compound
hydrochloride
formula
crystallization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780037239.8A
Other languages
English (en)
Other versions
CN109311852B (zh
Inventor
朱益忠
汤剑秋
刘飞
张喜全
顾红梅
朱波
王路路
汤松
张艳阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN109311852A publication Critical patent/CN109311852A/zh
Application granted granted Critical
Publication of CN109311852B publication Critical patent/CN109311852B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

本申请属于医药化学领域，涉及作为EGFR抑制剂的苯胺嘧啶化合物的结晶，具体而言，本申请涉及N‑(2‑((2‑(二甲基氨基)乙基)(甲基)氨基)‑4‑甲氧基‑5‑(4‑(3‑甲基‑2‑氧代‑2，3‑二氢‑1H‑苯并[d]咪唑‑1‑基)嘧啶‑2‑基氨基)苯基)丙烯酰胺(式I)盐酸盐的结晶A、结晶B和结晶C，还涉及结晶A、结晶B和结晶C的制备方法、包含该结晶A、结晶B或结晶C的结晶组合物、包含该结晶A、结晶B和结晶C或其结晶组合物的药物组合物以及它们的医药用途。本申请的结晶A、结晶B和结晶C具有纯度高、结晶度高、稳定性好等优点。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201780037239.8A 2016-06-24 2017-06-23 作为egfr抑制剂的苯胺嘧啶化合物的结晶 Active CN109311852B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610470835.2A CN107540661A (zh) 2016-06-24 2016-06-24 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN2016104708352 2016-06-24
PCT/CN2017/089693 WO2017220007A1 (zh) 2016-06-24 2017-06-23 作为egfr抑制剂的苯胺嘧啶化合物的结晶

Publications (2)

Publication Number Publication Date
CN109311852A true CN109311852A (zh) 2019-02-05
CN109311852B CN109311852B (zh) 2021-04-02

Family

ID=60783319

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610470835.2A Pending CN107540661A (zh) 2016-06-24 2016-06-24 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN201780037239.8A Active CN109311852B (zh) 2016-06-24 2017-06-23 作为egfr抑制剂的苯胺嘧啶化合物的结晶

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610470835.2A Pending CN107540661A (zh) 2016-06-24 2016-06-24 作为egfr抑制剂的苯胺嘧啶化合物的结晶

Country Status (9)

Country Link
US (2) US20190256497A1 (zh)
EP (1) EP3476841A4 (zh)
JP (1) JP2019518776A (zh)
KR (1) KR20190021345A (zh)
CN (2) CN107540661A (zh)
AU (1) AU2017282903B2 (zh)
CA (1) CA3028015A1 (zh)
RU (1) RU2019100065A (zh)
WO (1) WO2017220007A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN110698461B (zh) * 2018-07-09 2024-04-05 上海翰森生物医药科技有限公司 第三代egfr抑制剂的制备方法
CN113521074A (zh) * 2020-04-17 2021-10-22 南京圣和药业股份有限公司 一种包含喹啉类TGF-β1抑制剂的组合物及其用途
WO2023061433A1 (zh) * 2021-10-14 2023-04-20 齐鲁制药有限公司 一种egfr抑制剂的多晶型

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702990A (zh) * 2011-07-27 2014-04-02 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN105085489A (zh) * 2014-11-05 2015-11-25 上海页岩科技有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ710636A (en) * 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
JP6215938B2 (ja) * 2012-08-06 2017-10-18 エイシア バイオサイエンシーズ インコーポレイテッド プロテインキナーゼの阻害剤としての新規ピロロピリミジン化合物
CA2992317A1 (en) * 2015-07-16 2017-01-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Aniline pyrimidine derivatives and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702990A (zh) * 2011-07-27 2014-04-02 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN105085489A (zh) * 2014-11-05 2015-11-25 上海页岩科技有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途

Also Published As

Publication number Publication date
AU2017282903B2 (en) 2021-03-25
US20200361908A1 (en) 2020-11-19
EP3476841A4 (en) 2020-01-22
CA3028015A1 (en) 2017-12-28
JP2019518776A (ja) 2019-07-04
CN107540661A (zh) 2018-01-05
WO2017220007A1 (zh) 2017-12-28
KR20190021345A (ko) 2019-03-05
CN109311852B (zh) 2021-04-02
RU2019100065A (ru) 2020-07-24
RU2019100065A3 (zh) 2020-09-25
AU2017282903A1 (en) 2019-02-07
EP3476841A1 (en) 2019-05-01
US20190256497A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
JP4276376B2 (ja) 複素環式化合物及びそれを有効成分とする抗腫瘍剤
TWI739753B (zh) 苯胺嘧啶衍生物及其用途
US20200361908A1 (en) Crystals of aniline pyrimidine compound serving as egfr inhibitor
CN108047201A (zh) 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
WO2014025128A1 (ko) Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2013170671A1 (zh) 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
WO2008106635A1 (en) Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors
CN109311891A (zh) 作为jak抑制剂的吡咯并嘧啶化合物的结晶
WO2014082578A1 (zh) 杂芳基炔烃化合物及其应用
KR20180021743A (ko) 프테리디논 유도체인 표피 생장 인자 수용체 억제제의 응용
CA3059283A1 (en) C5-anilinoquinazoline compounds and their use in treating cancer
WO2021017996A1 (zh) 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
WO2020228635A1 (zh) 一种egfr激酶抑制剂及其在制备抗癌药物方面的应用
WO2020001351A1 (zh) Egfr抑制剂及其制备和应用
CN113461661B (zh) 6-(吡啶-3-基)喹唑啉-4(3h)-酮类衍生物及其制备和应用
KR101789934B1 (ko) 상피세포성장인자수용체 변이체를 가진 종양 진단 및 종양 성장 억제 활성을 갖는 신규 화합물 및 이를 포함하는 의학적 용도
CN110642838B (zh) Egfr抑制剂及其制备和应用
CN113227073B (zh) Egfr酪氨酸激酶的选择性抑制剂的盐及其晶型
CN108430987A (zh) Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
CN107663207B (zh) 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法
KR20220159457A (ko) Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도
CN116655600A (zh) 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1260821

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant